Concordia Pharma Gets False Ad Trial Award Upped To $2.2M
Law360, Los Angeles (March 2, 2017, 8:00 PM EST) -- Concordia Pharmaceuticals Inc. on Thursday saw its $730,000 damages award against Method Pharmaceuticals LLC trebled to $2.2 million when a Virginia federal judge said an enhancement was warranted in the false advertising suit over Method’s representation its irritable bowel syndrome medication was a valid generic substitute.
While U.S. District Judge Glen E. Conrad granted Concordia enhanced damages based off its April jury win, he stopped short of granting the pharmaceutical company attorneys’ fees, saying the case did not meet the “exceptional” standard established by Octane Fitness.
“The court believes that this enhanced award is necessary to fairly and adequately compensate Concordia...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!